Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the three and six months ended June 30, 2015 and provided an update on its corporate activities and product pipeline. Second Quarter 2015 and Subsequent Highlights Initiated Phase 1 Study of Lead Antifungal Product Candidate CD101 IV: In August, Cidara announced the initiation of a Phase 1, randomized, double-blind, dose-escalation study to determine the safety, tolerability,…

- Sixteen abstracts summarize evaluations of company's novel echinocandin CD101 and Cloudbreak™ immunotherapy platform - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today that results of nonclinical studies of two formulations of CD101, a novel echinocandin, will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, September 17-21, 2015.…

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced it will be participating in the Wedbush PacGrow 2015 Healthcare Conference. Jeff Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at 12:45 p.m. EDT (9:45 a.m. PDT) on Wednesday, August 12, 2015 in New York. A live audio webcast and replay will be available in the Investors section on the company website at http://www.cidara.com. About Cidara Therapeutics Cidara is…

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the initiation of a Phase 1, randomized, double-blind, dose-escalation study to determine the safety, tolerability, and pharmacokinetics of CD101 IV in healthy subjects. “The advancement of our first product candidate into the clinic ahead of schedule is a significant next step toward our mission to address the urgent need for effective new antifungal treatments,” said Jeffrey Stein,…

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that it is set to join the Russell 3000®, Russell 2000®, and Russell Microcap® Indexes at the conclusion of the annual reconstitution of Russell indexes on June 26, 2015. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. The Russell 2000 Index measures the performance…

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today reported financial results for the quarter ended March 31, 2015 and provided an update on its corporate activities and product pipeline. First Quarter 2015 and Subsequent Highlights Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations for CD101 IV by FDA: On May 11, 2015, Cidara announced that the U.S. Food and Drug Administration (FDA) designated its lead antifungal product candidate, CD101 IV,…

-CD101 IV designated for treatment of serious or life-threatening Candida infections- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the company’s lead antifungal product candidate, CD101 IV, as a Qualified Infectious Disease Product (QIDP) with Fast Track status. The QIDP and Fast Track designations are for the use of CD101 IV in the…

Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced the pricing of its initial public offering of 4,800,000 shares of common stock, an increase of 800,000 shares from the number of shares originally offered, at a public offering price of $16.00 per share. The shares are expected to begin trading on the NASDAQ Global Market today (April 15, 2015) under the ticker symbol "CDTX." In addition, Cidara has granted…

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today that Robert J. Perez and Timothy R. Franson, M.D., have joined the company’s Board of Directors. “Mr. Perez and Dr. Franson are recognized leaders in the biotechnology and pharmaceutical industries and bring a wealth of complimentary operational experience to our board,” said Jeff Stein, Ph.D., chief executive officer of Cidara. “I have had the privilege to…

Proceeds Will Advance Novel Anti-Infectives into Clinical Studies Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today the completion of a $42 million private Series B financing. Participants in the financing comprise a syndicate of healthcare-dedicated institutional investors and include both new and existing investors in Cidara. “We appreciate the support and confidence demonstrated by our new and existing investors in this round,” said Jeff…